Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: the prospects and plans for J&J’s pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda; and Moderna’s co-founder shares tips on innovation.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 12 November 2021, including: the prospects and plans for Johnson & Johnson’s pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda Pharmaceutical Co. Ltd.; and Moderna, Inc.’s co-founder shares tips on innovation.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "No Way To Go But Grow: J&J Outlines Plans To Become A $60bn Pharma In 2025" - Scrip, 18 Nov, 2021.)

(Also see "Pharma Will Need To Embrace More Inward-Looking China" - Scrip, 24 Nov, 2021.)

(Also see "Takeda's Livtencity Approved For Refractory CMV Infection In Transplant Patients" - Scrip, 25 Nov, 2021.)

(Also see "Moderna Co-Founder Robert Langer’s Tips For Innovation" - Scrip, 22 Nov, 2021.)

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145484

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel